Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23778719 | 0.90 | ADORA1 (0.50) | MTNR1AMTNR1BTSHRADORA3ADORA2A | |
| SCHEMBL23778696 | 0.88 | MTNR1A (0.50) | MTNR1AMTNR1BTSHRLMNA | |
| SCHEMBL23778716 | 0.86 | MTNR1A (0.45) | MTNR1AMTNR1BTSHRADORA3ADORA2A | |
| SCHEMBL23778721 | 0.84 | ADORA3 (0.45) | MTNR1AMTNR1BTSHRADORA3ADORA1 | |
| SCHEMBL23778693 | 0.83 | HPGD (0.58) | ADORA3ADORA2AADORA1LMNATP53 | |
| SCHEMBL23778733 | 0.83 | THRB (0.45) | MTNR1ATSHRADORA3LMNATP53 | |
| SCHEMBL23778715 | 0.82 | MTNR1A (0.48) | MTNR1AMTNR1BTSHRADORA3ADORA2A | |
| SCHEMBL23778706 | 0.82 | HPGD (0.43) | MTNR1AMTNR1BTSHR | |
| SCHEMBL23778678 | 0.80 | HPGD (0.40) | MTNR1AMTNR1BTSHRTP53 | |
| SCHEMBL23778705 | 0.76 | GSK3B (0.41) | MTNR1AMTNR1BTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | claimed |
| EP-3873890-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | Ahammune Biosciences Private Limited (IN) | 2021-09-08 | — | — | EP | claimed |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2026-01-01 | — | — | US | disclosed |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2021-12-09 | — | — | US | disclosed |
| EP-3873890-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | Ahammune Biosciences Private Limited (IN) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | IDO1, IDO2, NFATC1 | MTNR1A 1790/4885MTNR1B 1398/4885EPHX2 2655/4885 |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | MALT1, ADRM1, CYP11B1 | MTNR1A 306/4885MTNR1B 455/4885EPHX2 2743/4885 |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | IDO1, IDO2, NFATC1 | MTNR1A 2087/4885MTNR1B 1749/4885EPHX2 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.